SUMMARY

- The overlap of the 340B Drug Pricing Program and the Medicaid Drug Rebate program creates the possibility of duplicate discounts, which are prohibited under federal law.
- States are federally mandated to seek federal drug rebates on managed care Medicaid claims, meaning that the potential for duplicate discounts exists for managed care claims.
- Louisiana uses the Health Resources and Services Administration's (HRSA) Medicaid Exclusion File (MEF) for both Fee-for-Service (FFS) and managed care Medicaid claims in order to prevent duplicate discounts.
- Contract pharmacies are not permitted to bill Medicaid for drugs purchased at 340B pricing. This includes both FFS and managed care Medicaid.
- Starting July 15, 2019, pharmacy claims submitted by pharmacies on the MEF for hepatitis C virus direct acting antiviral (DAA) agents will deny.

340B & DRUG REBATE PROGRAM BACKGROUND

The national Medicaid Drug Rebate program was established in 1991 as a means to offset both state and federal Medicaid drug expenditures. When a drug manufacturer enters into a national rebate agreement, they are also required to enter into agreements with the 340B Drug Pricing Program.

The 340B Drug Pricing Program was designed to enable participating providers, referred to as “covered entities,” to stretch scarce federal resources by obtaining covered outpatient drugs at significantly discounted prices. This program is administered by HRSA’s Office of Pharmacy Affairs (OPA).

When a covered entity bills Medicaid for a pharmacy or outpatient physician-administered drug, the possibility of duplicate discounts exists due to the overlap of the Medicaid Drug Rebate and 340B Drug Pricing Programs. Therefore, when a covered entity enrolls in the 340B program, it must choose whether it will “carve-in” or “carve-out” its Medicaid patients. Carve-
in means that all drugs dispensed to Medicaid patients were purchased under the 340B Drug Pricing Program, while carve-out means that no drugs dispensed to Medicaid patients were purchased under the 340B Drug Pricing Program.

Additional information on the 340B Drug Pricing Program can be found at http://www.hrsa.gov/opa.

**MEDICAID EXCLUSION FILE**

HRSA communicates carve-in designations to states via the Medicaid Exclusion File (MEF) in order to alert states that Medicaid Drug Rebates should not be sought on MEF providers’ drug claims.

When a covered entity chooses to carve-in, it must provide HRSA with the National Provider Identification (NPI) and/or Medicaid provider number for each site that carves in for the purpose of inclusion in the MEF. An entry in the MEF indicates that a covered entity has chosen to carve-in for a single quarter.

A covered entity can change its carve-in or carve-out designation at any time; however, HRSA stipulates that the effective date of any such change will be the first day of a calendar quarter. Status changes for the next calendar quarter must be provided by the 15th day of the month preceding the quarter’s start (March 15, June 15, Sep. 15 and Dec. 15). Changes submitted after this date will not be effective until the start of the second quarter following the change. Because the MEF is produced on the 15th day of the month preceding a quarter’s start, this ensures that an entity’s carve-in or carve-out election is properly reflected on the applicable quarter’s MEF.

States can elect to identify 340B claims using methods other than the exclusion file (e.g. claim level indicators). Louisiana currently uses the MEF as the sole means of identifying 340B drug claims.

Additional information regarding the MEF can be found at https://www.hrsa.gov/opa/updates/2015/october.html.

**MANAGED CARE MEDICAID**

Section 2501(c) of the Patient Protection and Affordable Care Act (ACA) requires state Medicaid agencies to seek rebates on drugs dispensed by Medicaid managed care organizations (MCO). This means that the potential for duplicate discounts exists for both FFS and managed care Medicaid.

Due to this duplicate discount potential, Louisiana requires that covered entities utilize the same carve-in or carve-out designation for managed care Medicaid patients as for FFS.
Medicaid patients. If a covered entity appears on the MEF, Louisiana will exclude that provider’s FFS and MCO claims from rebate invoicing. Since claims for FFS Medicaid and managed care Medicaid recipients are treated identically in regard to exclusion from rebate invoicing, any reference to “Medicaid recipients” in this document refers to both FFS and managed care Medicaid recipients.

In order to allow covered entities to identify managed care Medicaid patients from an MCO’s private insurance patients, Louisiana requires its MCOs to utilize a unique Processor Control Number (PCN) or group number for Louisiana Medicaid.

Louisiana Medicaid FFS and MCO BIN, PCN, and group numbers for pharmacy claims:

<table>
<thead>
<tr>
<th>Plan Name</th>
<th>PBM Name</th>
<th>BIN</th>
<th>PCN</th>
<th>Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>AETNA</td>
<td>CVS Health</td>
<td>610591</td>
<td>ADV</td>
<td>RX8834</td>
</tr>
<tr>
<td>AMERIHEALTH CARITAS LA</td>
<td>PerformRx</td>
<td>0195595</td>
<td>06030000</td>
<td>n/a</td>
</tr>
<tr>
<td>HEALTHY BLUE</td>
<td>CVS</td>
<td>020107</td>
<td>FG</td>
<td>WKLA</td>
</tr>
<tr>
<td>LA HEALTHCARE CONNECTIONS</td>
<td>CVS Caremark</td>
<td>004336</td>
<td>MCAIDADV</td>
<td>RX5444</td>
</tr>
<tr>
<td>UNITED HEALTHCARE</td>
<td>OptumRx</td>
<td>610494</td>
<td>9999</td>
<td>ACULA</td>
</tr>
<tr>
<td>FFS / LEGACY MEDICAID</td>
<td>n/a</td>
<td>610514</td>
<td>LOUIPROD</td>
<td>n/a</td>
</tr>
</tbody>
</table>

Payer ID can be utilized to identify managed care Medicaid recipients’ medical claims. Please refer to the Provider & Plan Resources page for information regarding Electronic Data Interchange (EDI) claim submissions.

CONTRACT PHARMACIES

HRSA permits covered entities to contract with one or more pharmacies to provide services to the covered entity’s patients in order to increase patient access to 340B drugs.

HRSA expressly prohibits contract pharmacies from dispensing drugs purchased under the 340B Drug Pricing Program to Medicaid recipients unless the covered entity, the contract pharmacy and the state Medicaid agency have established an arrangement to prevent duplicate discounts (75 FR 10272, March 5, 2010). Louisiana currently has no such agreements in place and requires that all contract pharmacies carve-out Medicaid recipients for both FFS and MCO 340B drug claims.

1Full text from Federal Register (FR) available at www.federalregister.gov
Effective Sept. 12, 2017, pharmacy claims should deny at Point of Sale (POS) if 340B indicators are on the claim but the pharmacy is not listed in the MEF. These claims should be filled with regular pharmacy stock, not 340B stock, and billed accordingly.

**CURRENT BILLING GUIDELINES**

For full billing procedures, please refer to each MCO’s provider manual.

**Carve-In**

**FFS Pharmacy**

Covered entities who carve-in Medicaid recipients should bill a drug’s actual acquisition cost in National Council for Prescription Drug Programs (NCPDP) field 409-D9 Ingredient Cost Submitted.

**MCO Pharmacy**

Covered entities who carve-in Medicaid recipients should bill according to the contract arrangements between the 340B covered entity and the MCO.

Contract pharmacies are not permitted to carve-in FFS or MCO Medicaid for drugs purchased at 340B prices.

**Hepatitis C Virus Direct Acting Antiviral (DAA) Agents**

Starting July 15, 2019, the Louisiana Hepatitis C Elimination Program will be implemented to address the public health crisis caused by hepatitis C. The Louisiana Departments of Health and Corrections have entered into a five-year contract with Asegua Therapeutics, a wholly owned subsidiary of Gilead Sciences Inc., to provide unrestricted access to its authorized generic of Epclusa (sofosbuvir/velpatisvir) for treatment of hepatitis C among Medicaid recipients and incarcerated patients. For Medicaid recipients, a supplemental rebate agreement was utilized. Therefore, as 340B Medicaid claims cannot be included in supplemental rebate agreements, claims for hepatitis C direct-acting antiviral agents from 340B pharmacies carved-in to Medicaid will deny at POS. Claims for hepatitis C direct-acting antiviral agents from 340B carve-out pharmacies are not subject to this limitation and will process as usual.

**Carve-Out and Contract Pharmacies**

Covered entities who carve-out Medicaid recipients and contract pharmacies should bill according to guidelines provided in each MCO’s provider manual for non-340B drug claims. Links have been provided below:
Aetna  http://www.aetnabetterhealth.com/louisiana/providers/manual


Healthy Blue  https://providers.healthybluela.com

Louisiana Healthcare Connections  http://www.louisianahealthconnect.com/for-providers/provider-resources/

United Healthcare  http://www.uhcommunityplan.com/health-professionals/la.html

Fee-for-Service  http://www.lamedicaid.com/provweb1/Providermanuals/Intro_Page.aspx

REIMBURSEMENT

Fee for Service (FFS)

As of May 1, 2017, FFS Pharmacy Outpatient claims for drugs purchased at 340B rates will be reimbursed at Actual Acquisition Cost plus a professional dispensing fee or Usual and Customary, whichever is less.

Reimbursement methodologies for physician-administered drugs will not change.

Outpatient hospital claims for physician-administered drugs will continue to be paid using a cost to charge methodology on the interim and are settled at cost during final settlement. FQHC and RHC claims for physician-administered drugs will be included in the all-inclusive T1015 encounter rate as they are currently.

Providers can also contact the appropriate department listed below for further information:

<table>
<thead>
<tr>
<th>FFS Program</th>
<th>Reimbursement Questions Contact</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmacy</td>
<td>Pharmacy Help Desk</td>
<td>1-800-437-9101</td>
</tr>
<tr>
<td>All Others (Hospital, Professional Services, etc.)</td>
<td>DXC Technology Provider Relations</td>
<td>1-800-473-2783</td>
</tr>
</tbody>
</table>

Managed Care

Managed care reimbursements are made in accordance with contractual arrangements between the covered entity and MCO.
For questions about reimbursement, please contact the provider relations department of the appropriate MCO.

<table>
<thead>
<tr>
<th>Name</th>
<th>Provider Relations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aetna</td>
<td>1-855-242-0802</td>
</tr>
<tr>
<td>AmeriHealth Caritas</td>
<td>1-888-922-0007</td>
</tr>
<tr>
<td>Healthy Blue</td>
<td>1-844-521-6942</td>
</tr>
<tr>
<td>Louisiana Healthcare Connections</td>
<td>1-866-595-8133</td>
</tr>
<tr>
<td>United Healthcare</td>
<td>1-866-675-1607</td>
</tr>
</tbody>
</table>

**POLICY COMPLIANCE**

Noncompliance with this policy may result in recoupments, sanctions and/or other disciplinary action taken against the provider.

**CLAIM-LEVEL INDICATORS**

A covered entity’s Medicaid claims may not be exclusively 340B because of orphan drug regulations, 340B drug stock shortages and other billing issues. 340B claim-level indicators shall be entered to identify drug claims that should be excluded from the rebate invoicing process.

Beginning with date of service Sept. 12, 2017, providers shall submit both FFS and managed care claims with the following claim-level indicators below. Claim level indicators will NOT be used for rebate invoicing purposes and are utilized for claims processing purposes only at this time.

**Pharmacy Claims**

340B Pharmacy claims shall contain BOTH indicators below:

<table>
<thead>
<tr>
<th>NCPDP Field</th>
<th>NCPDP Field Name</th>
<th>NCPDP Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>420-DK</td>
<td>Submission Clarification Code</td>
<td>20 = 340B</td>
</tr>
<tr>
<td>423-DN</td>
<td>Basis of Cost Determination</td>
<td>08 = 340B Disproportionate Share Pricing</td>
</tr>
</tbody>
</table>
**Physician-Administered Drug Claims**

Providers shall submit the UD modifier to identify 340B drugs on outpatient physician-administered drug claims. This includes outpatient professional service 340B drug claims. Due to the cost to charge methodology, outpatient hospital claims are excluded from the claim level indicator requirement.

- CMS 1450/UB04: Enter UD Modifier immediately following drug HCPCS/CPT code in field 44. For example, HCPCS J1111 billed as J1111UD.
- CMS 1500: Enter HCPCS code in field 24C followed by the UD Modifier.
- 837I: Loop 2400 SV2 can send up to four modifiers SV202-3, SV202-4, SV202-5, and SV202-6.
- 837P: Loop 2400 SV1 can send up to four modifiers in SV101-3, SV101-4, SV101-5, and SV101-6.

**QUESTIONS**

If you have questions about the contents of this memo, you may contact:

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Email</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Brian Hanner,</strong> Drug Rebate Coordinator</td>
<td><strong><a href="mailto:Brian.Hanner@la.gov">Brian.Hanner@la.gov</a></strong></td>
<td>225-342-1815</td>
</tr>
<tr>
<td><strong>Medicaid Pharmacy Help Desk</strong></td>
<td><strong><a href="mailto:Medicaid.Pharmacy@la.gov">Medicaid.Pharmacy@la.gov</a></strong></td>
<td>1-800-437-9101</td>
</tr>
</tbody>
</table>
**Managed Care Organizations Electronic Data Interchange Submissions**

**Aetna Better Health of Louisiana**  
Payer ID 128LA

Emdeon [www.emdeon.com](http://www.emdeon.com) 1-877-469-3263

Emdeon is the EDI vendor we use. Providers need to contact the software vendor directly for further questions about their electronic billing. All electronic submissions shall be submitted in compliance with applicable law including HIPAA regulations and Aetna Better Health of Louisiana policies and procedures. If you use a clearinghouse other than Emdeon, please have them call Emdeon at the following number in order to establish connectivity: 1-800-845-6592. (Please run a test claim prior to submitting batches.) Please use the Payer ID above when submitting claims to Aetna Better Health of Louisiana. For pharmacy resources, visit [https://www.caremark.com/wps/portal](https://www.caremark.com/wps/portal) and click on Pharmacists & Medical Professionals.

**AmeriHealth Caritas**  
Payer ID 27357

Trading Partner:  
Change Healthcare

For ACLA EDI questions:  
Email – edi@amerihealthcaritasla.com  
ACLA EDI Phone – 1-866-428-7419  
Change Healthcare Phone – 1-877-363-3666

**Healthy Blue**

Trading Partners:  
Emdeon (formerly WebMD) – Claim Payer ID 27514  
Capario (formerly MedAvant) – Claim Payer ID 28804  
Availity (formerly THIN) – Claim Payer ID 26375  
Smart Data Solutions – Claim Payer ID 81237

A provider may contact the Healthy Blue EDI Hotline at 1-800-470-9630 to start the electronic claims submission process, or with any questions.

**Louisiana Healthcare Connections**  
Payer ID 68069

Trading Partners:  
Emdeon/Change Healthcare  
MedAvant/Capario/Emdeon  
Availity  
Gateway EDI/TriZetto  
Smart Data Solutions  
Infendi  
Experian  
Encoda  
ClaimRemedi  
Allscripts/PayerPath  
ViaTrack  
GHN-Online/Greenway Eligibility
MD On-line/Ability  Relay Health/McKesson  Practice Insight
SSI              ZirMed             InMediata

For support: 1-800-225-2573 Ext. 6075525 or via email at EDIBA@centene.com.

**UnitedHealthcare**
**Payer ID 87726**

For EDI questions or list of clearinghouses:
Phone – 1-800-842-1109 or 1-800-210-8315
Email – ac_edi_ops@uhc.com

Current Trading Partners include (but not limited to):

<table>
<thead>
<tr>
<th>Allscripts</th>
<th>Availity</th>
<th>Capario</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emdeon</td>
<td>Gateway EDI/TriZetto</td>
<td>MD Online</td>
</tr>
<tr>
<td>MedAssets</td>
<td>Navicure</td>
<td>Office Ally</td>
</tr>
<tr>
<td>OptumInsight</td>
<td>Practice Insight</td>
<td>RealMed</td>
</tr>
<tr>
<td>RelayHealth</td>
<td>SSI</td>
<td>ZirMed</td>
</tr>
</tbody>
</table>